RESPIRI

wheezo®

ASX: RSH
OTCQB: RSHUF

USA Ready Providing Care Beyond the Clinic

Delivering scalable **reimbursed** RPM solutions to improve outcomes and reduce healthcare burden

Reducing healthcare costs through technology

March 2023
Marjan Mikel (RESPIRI CEO)

Forward Looking

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri's current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services.

These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release.

The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Business Ready

USA Commercialisation Milestones Achieved

Clinical & Regulatory

- ✓FDA approved Class II device (wheezo®)
- ✓Validated wheezo® device
- ✓Validated platform & patient mobile application

RPM Program Design Proven

- ✓Patients highly compliant
- ✓Physician led
- ✓Lead patient-clinical indicator positive results
- ✓Cost benefits

US Market Requirements

- ✓Qualifies for CMS RPM CPT code reimbursement
- ✓CMS paid services
- ✓Physicians paid
- ✓3rd party RPM outsourcing
- ✓RPM marketing/ sales partners

Commercial Pipeline

- ✓8 Health Care Organisation (HCO) Clients secured
- ✓Wheezo RPM patient roll out commencing
- ✓6 imminent deals
- ✓Board Specialist types & US States.
- ✓Additional healthcare partners
- ✓Recurring mthly revenue + device sales **now**
- ✓Strong pipeline

RPM Program Roll-Out

- ✓Proven Executive Team
- ✓Patients onboarded
- ✓Program working
- ✓Reimbursement claimed & paid
- ✓Scale-ready
- ✓Inventory

>>Rich pipeline & now scaling

2023 USA Progress Report Card

- Full wheezo RPM program patient onboarding commencing in Michigan Children's Hospital (Part of the Tenet Hospital Group)
  - Approx 8,000 new patient consultations p.a.
  - April Hospital Clinic
  - April/May outpatient clinics

- Full wheezo RPM patient onboarding commenced in
  - Arkansas Heart Hospital March 2023
  - North Carolina Healthcare Organisation March 2023

- Onboarding Approx. 100 patients now

- **Contract secured** with a new major home & transition care provider in an additional US State

- Contract finalisation with major respiratory clinic group
  - **100+ clinics across USA**

2023 USA Progress Report Card

- 4 new Clinical Services Companies marketing/sales partners with existing clientele across numerous states **contract discussions/finalisation**
  - Additional 15 US states coverage
  - Innovative School asthma program in Atlanta and surrounding states
  - Telehealth practice management providers wishing to expand offering
  - Existing nursing home care nursing team of 150

- **Advanced RPM discussions with 2 private health insurers.**
  - NASDAQ listed Third Party Administrator (TPA) Employer-funded health plans
    - Clinical Care nursing support to improve outcomes and savings
  - Major national insurer state office
  - Cost minimalization program
  - Possible Risk Sharing arrangement

- Head of US Operations employed
  - Extensive executive search completed.
  - Extensive RPM/MedTech/Healthcare institution track record
  - Commencing mid-April
  - Maintain consistent USA business momentum

RESPIRI

A MEDICAL DEVICES & SAAS COMPANY

Respiratory Disease: A significant burden to the US healthcare system

Addressable market



Abbreviations: COPD, chronic obstructive pulmonary disease; CPT, current procedural terminology; RPM, remote patient monitoring; *CMS, Centers for Medicare & Medicaid Services.*

The problem

- Respiratory disease represents a **$134.3Bn financial burden** on the health system
- **COPD one of the costliest - Estimated to total $49 billion in 2020**[6]
- Re-admission rates continue to put strain on US Health System, with 30-day **COPD re-admission** rates as high as 38%.
- **Cost blow-outs:** every in-hospital COPD patient stay costs on average **USD $28k** per event[7]



- Less than **2% of Providers** have tapped into RPM CPT code reimbursement opportunity and those that have, on average, have onboarded **20 patients**
- **Programs are not optimised -** Medicare (CMS data) showing that on average patients meet thresholds to support claimable events **36% of the time** (in a rolling 12-month period)

RESPIRI

References: 1. CDC. *COPD* (accessed 29 Nov 2022); 2. CDC. *Asthma* (accessed 29 Nov 2022); 3. May S & Li J. *Allergy Asthma Proc.* 2015; 4. Yoo J, et al. *Aust J Gen Pract.* 2019; 5. Bednarek M, et al. *Thorax*. 2008; 6. Larsen D, et al . *The quality of care and economic burden of COPD in the United States: Considerations for managing patients and improving outcomes, American Health & Drug Benefits. Available at: https://www.ahdbonline.com/issues/2022/june-2022-vol-15-no-2/3223-the-quality-of-care-and-economic-burden-of-copd-in-the-united-states-considerations-for-managing-patients-and-improving-outcomes (Accessed: December 5, 2022).*'; 7. Syamlal G, et al. *MMWR Morb Mortal Wkly Rep.* 2020;69(26):809-814;

Remote Patient Monitoring (RPM)
A growth opportunity that benefits healthcare organizations & patients

The Opportunity
RPM market CAGR 30%+
Is projected to reach USD $80B 2026







Centres for Medicare & Medicaid Services (CMS) reimburse RPM across all of USA

US payors understand & fund preventative medicine because ED or in-hospital stay costs are expensive for providers

Physicians can outsource RPM to 3rd parties
Platforms that integrate and scale with minimal provider engagement will win

Shown to Improve Outcomes in a Variety of Chronic Disease States
including Asthma[1,2] and COPD[3]

Remote Patient Monitoring can:

- ✓ Track disease progression[5]
- ✓ Assist in early identification of clinical exacerbation[3]
- ✓ Increase patient confidence[2]
- ✓ Increase shared decision-making[3]
- ✓ Deliver personalized healthcare solutions[4]

RESPIRI

Abbreviations: RPM, Remote Patient Monitoring; COPD, Chronic obstructive pulmonary disease , CAGR, Compound annual growth rate

References: **1.** Vegesna 2017 **2.** Liu 2011 **3.** Walker 2019 **4.** Moses 2021 **5.** Majumder 2019

RPM IS GENEROUSLY REIMBURSED

Established and economically favorable

RPM CPT Code	Descriptor	Fees
99453	Patient set up (once per episode of care)	$19.04
99454	Device delivery/supply (every 30 days, min.16 days of data collection)	$55.72
99457	Patient Monitoring & interactive communication. First 20 mins (every 30 days)	$50.18
99458	Patient Monitoring & Communication. Each additional 20 mins (every 30 days)	$40.84
99091	Collection & Review of Physiological Data (every 30 days)	$56.88

CCM CPT Code	HCP requirement	Fees
99490	20 mins	$62
99490+ 99439	40 mins	$109
99490+ 99439 (x2)	60 mins	$156
G0511	20 mins Rural	$76

Generates up to $2,500/patient pa. $2.5M/1,000 patients

Entire RPM program can be outsourced to our 3rd party financially and resource de-risking for institution

1 **Provider sets patient up on a remote monitoring platform/system**

Provider bills
ONCE

2 **Physiological data is captured/recorded over at least 16 days**

Provider bills
MONTHLY

3 **Data sent in real time & clinical staff review RPM data & interact with the patient**



Provider bills
MONTHLY

RESPIRI

Remote Patient Monitoring (RPM)
Adoption yet to reach full potential

RPM is underutilized

- ✓ New (introduced 2019)
- ✓ No easy-to-use devices for patients which reduce subjectivity AND provide objective measures
- ✓ RPM perceptions for HCOs creating barriers to adoption

Many clinics, HCOs still building an understanding of RPM

Need practical solutions for patients to use when they are away from the clinic (traditional methods require trained physicians to facilitate)

RPM Providers who can demonstrate simple integration and scale with low impact on existing workflow and staffing will win

RESPIRI

Abbreviations: RPM, Remote Patient Monitoring;

introducing wheezo® a new way to detect wheeze remotely

- Provides an objective & accurate method for assessing wheeze[3]
- A first for respiratory - integrates into RPM





wheezo® breath sensor
- FDA Cleared March 2021, Class II, (510k, k202062)

- Patient records breath sounds using simple tidal breathing

- Non-invasive, easy to use

wheezo® is intended to detect and record abnormal breath sounds (continuous adventitious breath sounds/CABS) at the windpipe(trachea), reported as WheezeRate in adults & children ≥2 years.

respiri™ app
- Runs algorithm to detect abnormal breath sounds & reports a WheezeRate[1]

- Additional features deliver objective measures e.g., health tools, self-reported symptoms, triggers & medication adherence, action plan

Your healthcare professional's advice is required to understand wheezo® readings.

Algorithm detects wheeze remotely as well as experienced respiratory specialists[2]

- Works by analyzing breath recording spectrogram[3]
  - Accuracy 91%
  - Specificity 93%
  - Sensitivity 87%
  - Cohen's Kappa Coefficient 0.81

Integrates into existing health systems e.g., EPIC

- HCP access to patient level data, enabling data review (including listening to breath recordings) whilst patients are in the community

- Secure cloud storage

RESPIRI

1. Wheezo Owner Manual US-HCO. WZO01-0014. Version 1
2. Data on File.
3. Data on File.

Remote Patient Monitoring (RPM)

Program design for respiratory

A low touch, scalable RPM solution supporting patients in the community whilst reducing unplanned hospital visits

Program readiness
- Seamless Integration into EMR/EHR
- Patient eligibility and identification
- Program setup and patient support

Patient enrollment
- Onboarding (account setup, program expectations, device training, etc)
- Device allocation (inc. shipping if app)

Reporting & billing
- Reporting to support
  - Utilization of device(s)
  - Program performance
  - Impact on customer objectives
- Billing files for simplified claiming

Utilization and remote monitoring
- Recurring scheduled consults with patients
- Review device usage and health data
- Escalate to providers by exception (managed by RPM provider)

Providers

Remote Patient Monitoring (RPM) Total Solution

- Integrated Class II FDA cleared medical devices
- Accredited clinical staff
- Secure, HIPPA compliant end-to-end platform

RESPIRI

Leadership Team. Proven Track record

Healthcare/RPM execution

Global & USA experienced with 35 years in healthcare from large corporate to start-ups with a focus on Remote Patient Monitoring, medical devices & businesses SaaS, pharmaceuticals. Executed many large healthcare & SaaS commercial transactions

Marjan Mikel
Chief Executive Officer & Managing Director

MBA-educated, internationally experienced business leader with a track record of building & growing innovative B2B technology businesses across a range of industrial applications

Peter Hildebrandt
Chief Operations Officer

Technology executive with a track record of leading high performing international technology organizations. With a diverse experience in both established and progressive technologies.

George Vlachodimitropoulos
Chief Technology Officer

Proven Senior Commercial Executive with a career spanning industries including MedTech & Health SaaS, Pharmaceuticals and. Deep expertise in strategy, sales, start-up to scale and leading for success

Theo Antonopoulos
Chief Commercial Officer

Biomedical engineer with both academic & practical experience in design and development of medical devices under FDA ISO compliant quality systems. Actively participating in design and development of hardware, firmware and software used in monitoring respiratory symptoms

Samaneh Sarraf
Chief Research Officer

RESPIRI

Respiri is USA Business Ready & Delivering

Clinical & Regulatory

- ✓FDA approved Class II device (wheezo®)
- ✓Validated wheezo® device
- ✓Validated platform & patient mobile application

RPM Program Design Proven

- ✓Patients highly compliant
- ✓Physician led
- ✓Lead patient-clinical indicator positive results
- ✓Cost benefits

US Market Requirements

- ✓Qualifies for CMS RPM CPT code reimbursement
- ✓CMS paid services
- ✓Physicians paid
- ✓3rd party RPM outsourcing
- ✓RPM marketing/ sales partners

Commercial Pipeline

- ✓HCO Clients secured x 8
- ✓Wheezo RPM patient roll out commencing
- ✓6 imminent deals
- ✓Board specialty types & geog.
- ✓Additional healthcare partners
- ✓Recurring mthly revenue + device sales **now**
- ✓Strong pipeline

RPM Program Roll-Out

- ✓Proven Executive Team
- ✓Patients onboarded
- ✓Program working
- ✓Reimbursement claimed & paid
- ✓Scale-ready
- ✓Inventory

>>Rich pipeline & now scaling

Disclaimer statement

This report identifies some of the major risks associated with an investment in the Company. The risk factors below ought not to be taken as exhaustive of the risks faced by the Company or by investors in the Company.

Speculative nature of investment: An investment in Shares of the Company should be considered very speculative. No assurance as to future profitability or dividends can be given as they are dependent on successful product development, future earnings and the working capital requirements of the Company. The Board does not envisage in the immediate future that the Company will generate sufficient revenue to be profitable or be in a position to declare any dividends. The financial prospects of the Company are dependent on a number of factors, including successfully completing further product development, gaining regulatory approvals, the degree of market acceptance or take-up of its products and the amount of competition encountered from competitive or alternative products developed by third parties. There is no guarantee that the Company's development work will result in commercial sales or that the Company will achieve material market penetration.

Competition: The medical device and digital health industries are highly competitive and include companies with significantly greater financial, technical, human, research and development, and marketing resources than the Company. There are companies that compete with the Company's efforts to develop, and commercialise its products.

Reliance on Key Personnel & Service Providers: The Company currently employs a small number of key personnel, and the Company's future depends on retaining and attracting suitably qualified personnel. There is no guarantee that the Company will be able to attract and retain suitably qualified personnel, and a failure to do so could materially and adversely affect the business, operating results and financial prospects. The Company operates a significant amount of its key activities through a series of contractual relationships with independent contractors and suppliers. All of the Company's contracts carry a risk that the third parties do not adequately or fully comply with its or their respective contractual rights and obligations. Such failure can lead to termination and/or significant damage to the Company's product development efforts.

Sufficiency of Funding: The Company has limited financial resources and will need to raise additional funds from time to time to finance the complete development and commercialisation of its products. The Company's ability to raise additional funds will be subject to, among other things, factors beyond the control of the Company and its Directors, including cyclical factors affecting the economy and share markets generally. The Directors can give no assurance that future funds can be raised by the Company on favourable terms, if at all.

Technological Development: Medical device research and product development involve scientific, software and engineering uncertainty and long lead times. There is no certainty as to whether any particular event or project will occur within a set period or by a certain date.

Regulatory Risk: Medical device products are regulated by government agencies and must be approved prior to commercial sales. Complex government health regulations increase uncertainty and are subject to change at any time. As such the risk exists that the Company's new or existing products may not satisfy the stringent requirements for approval, the approval process may take longer than expected or previous approvals may be altered or revoked. This may adversely affect the Company's competitive position and the financial value of the medical devices to the Company.

Product Liability & Manufacturing Risks: As with all new products, even after the granting of regulatory approval, there is no assurance that unforeseen adverse events or manufacturing defects will not arise. Adverse events could expose the Company to product liability claims or litigation, resulting in the removal of the regulatory approval for the relevant products and/or monetary damages being awarded against the Company. In such event, the Company's liability may exceed the Company's insurance coverage. If any products do not meet suitability or quality assurance standards, this may result in increased costs and may delay sales.

Trade Secrets & Patents: The Company relies on its trade secrets and patent rights. It cannot be certain that others will not independently develop the same or similar technologies on their own or gain access to trade secrets or disclose such technology, or that the Company will be able to meaningfully protect its trade secrets and unpatented know-how and keep them secret. The Company's existing intellectual property rights include its copyright in source code used in its digital health technologies, its know-how in the development of digital health products and data arising from the use of its digital health products. There isno guarantee that the Company's intellectual property comprises all of the rights that the Company may require to freely commercialise its product candidates. The granting of a patent in one country does not mean the patent application will be granted in other countries and competitors may at any time challenge granted patents and a court may find that the granted patent is invalid or unenforceable or revoked.

Stock Market Volatility: The performance of the share market may affect the Company and the price at which its shares trade on a share market. The share market has in the past and may in the future be affected by a number of matters.

Customer contracts: The Company's ability to distribute and ultimately sell its products is subject to a small number of commercial agreements. There is a risk that these contracts could be breached, not complied with according to their terms, terminated or substantially modified in a way which adversely affects the ability for the Company to sell its products or creates a significant liability for the Company.

Respiri Limited Risk Factors

RESPIRI

A MEDICAL DEVICES & SAAS COMPANY

RESPIRI

Our Mission

We improve Respiratory Health by extending care beyond the clinic.

ASX: RSH
OTCQB: RSHUF

Our Vision

A Lifelong Partner For Our Patients.